Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 12/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978446 | 0.91 | PTGER1 (0.48) | FFAR4PTGER1MRGPRX4CYP1A2CYP3A4 | |
| SCHEMBL3977914 | 0.90 | MRGPRX4 (0.47) | PTGER1MRGPRX4FABP3FABP4FABP5 | |
| SCHEMBL3980353 | 0.86 | MRGPRX4 (0.53) | PTGER1MRGPRX4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3977132 | 0.85 | MRGPRX4 (0.49) | PTGER1MRGPRX4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3987229 | 0.85 | NR4A2 (0.48) | FFAR4ABL1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3978883 | 0.83 | ABL1 (0.46) | MRGPRX4ABL1 | |
| SCHEMBL3980074 | 0.82 | MRGPRX4 (0.57) | MRGPRX4ABL1 | |
| SCHEMBL3986731 | 0.82 | HTT (0.57) | MRGPRX4FABP3FABP4FABP5 | |
| SCHEMBL3982055 | 0.82 | PTGER4 (0.52) | — | |
| SCHEMBL5512186 | 0.82 | PTGER4 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756042-B1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8084476-B2 | Substituted methyl aryl or heteroaryl amide compounds | RAQUALIA PHARMA INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | RAQUALIA PHARMA INC. (JP) | 2009-06-25 | — | — | US | disclosed |
| US-7534914-B2 | Substituted methyl aryl or heteroaryl amide compounds | REQUALIA PHARMA INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1756042-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
| WO-2005105732-A1 | SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163558-A1 | Substituted Methyl Aryl or Heteroaryl Amide Compounds | PTGER1, PTGER2, PTGER3 | FFAR4 386/4885PTGER1 1/4885MRGPRX4 66/4885 |
| US-20050267170-A1 | Substituted methyl aryl or heteroaryl amide compounds | PTGER1, PTGER2, PTGER3 | FFAR4 386/4885PTGER1 1/4885MRGPRX4 66/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | FFAR4 38/4885PTGER1 5/4885MRGPRX4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.